The experimental eloralintide–tirzepatide combination produced encouraging sponsor-reported results in adults with type 2 diabetes. Treatment discontinuations and the analysis assumptions remain central to interpreting the findings.
Three editions daily.
Updated as the evidence changes.
Newly released TRIUMPH-2 findings strengthen evidence for the investigational drug in adults with excess weight and type 2 diabetes. Different statistical analyses yield different weight-loss estimates, while long-term health benefits remain unresolved.
New research complicates the assumption that cellular recycling uniformly declines with age. Its preliminary findings also highlight why measuring biological activity does not automatically establish a health benefit.
The announcement marks the platform’s entry into human testing. The candidate and trial details remain undisclosed, and no human results were released.
A September 28 research update highlights a small randomized trial of noninvasive stimulation for uncontrolled hypertension. A possible benefit in a small subgroup remains preliminary.
Conceptual scientific illustration.
Not presented as study evidence.
Every consequential story carries a visible evidence grade, a primary-source trail and a plain-language account of what remains unknown.
Read our standards →Timely enough to matter.
Structured enough to be reliable.
Overnight research, journals and regulatory notices
Study analysis, explainers and claim checks
Breaking developments, context and what comes next
